Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Finch Therapeutics Group Inc (FNCH)

Finch Therapeutics Group Inc (FNCH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,693
  • Shares Outstanding, K 1,606
  • Annual Sales, $ 110 K
  • Annual Income, $ -74,750 K
  • 60-Month Beta 0.46
  • Price/Sales 37.37
  • Price/Cash Flow N/A
  • Price/Book 0.16
Trade FNCH with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.86 +23.66%
on 04/12/24
3.37 -31.75%
on 04/16/24
-0.10 (-4.17%)
since 04/03/24
3-Month
1.86 +23.66%
on 04/12/24
4.46 -48.43%
on 03/11/24
-0.38 (-14.34%)
since 02/02/24
52-Week
1.86 +23.66%
on 04/12/24
16.74 -86.26%
on 06/12/23
-8.66 (-79.01%)
since 05/03/23

Most Recent Stories

More News
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates

Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for...

FNCH : 2.30 (-7.63%)
ATNM : 8.96 (+2.40%)
Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of 3.70% and 2.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

IRWD : 8.12 (-2.17%)
FNCH : 2.30 (-7.63%)
Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why

Finch Therapeutics Group, Inc. (FNCH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

FNCH : 2.30 (-7.63%)
Finch Therapeutics to Participate in Upcoming June Investor Conferences

SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

FNCH : 2.30 (-7.63%)
Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

FDA lifted clinical hold on IND for CP101Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022$15 million drawn from...

FNCH : 2.30 (-7.63%)
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022

SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

FNCH : 2.30 (-7.63%)
Why Finch Therapeutics Stock Is Skyrocketing Today

The FDA, at long last, has lifted a clinical hold on Finch's C. diff program.

FNCH : 2.30 (-7.63%)
Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND

SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

FNCH : 2.30 (-7.63%)
Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs

SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

FNCH : 2.30 (-7.63%)
Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

FNCH : 2.30 (-7.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Finch Therapeutics Group Inc. is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery(R) platform to develop a novel class of orally administered biological drugs. The company's product candidate includes CP101, FIN-211, FIN-524 and FIN-525. Finch Therapeutics Group Inc....

See More

Key Turning Points

3rd Resistance Point 2.96
2nd Resistance Point 2.81
1st Resistance Point 2.55
Last Price 2.30
1st Support Level 2.14
2nd Support Level 1.99
3rd Support Level 1.73

See More

52-Week High 16.74
Fibonacci 61.8% 11.06
Fibonacci 50% 9.30
Fibonacci 38.2% 7.54
Last Price 2.30
52-Week Low 1.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar